| Literature DB >> 35070649 |
Joshua Kiddy K Asamoah1,2, Eric Okyere3, Afeez Abidemi4, Stephen E Moore5, Gui-Quan Sun1,6, Zhen Jin6, Edward Acheampong7, Joseph Frank Gordon8.
Abstract
Cost-effectiveness analysis is a mode of determining both the cost and economic health outcomes of one or more control interventions. In this work, we have formulated a non-autonomous nonlinear deterministic model to study the control of COVID-19 to unravel the cost and economic health outcomes for the autonomous nonlinear model proposed for the Kingdom of Saudi Arabia. We calculated the strength number and noticed the strength number is less than zero, meaning the proposed model does not capture multiple waves, hence to capture multiple wave new compartmental model may require for the Kingdom of Saudi Arabia. We proposed an optimal control problem based on a previously studied model and proved the existence of the proposed optimal control model. The optimality system associated with the non-autonomous epidemic model is derived using Pontryagin's maximum principle. The optimal control model captures four time-dependent control functions, thus, u 1 -practising physical or social distancing protocols; u 2 -practising personal hygiene by cleaning contaminated surfaces with alcohol-based detergents; u 3 -practising proper and safety measures by exposed, asymptomatic and symptomatic infected individuals; u 4 -fumigating schools in all levels of education, sports facilities, commercial areas and religious worship centres. We have performed numerical simulations to investigate extensive cost-effectiveness analysis for fourteen optimal control strategies. Comparing the control strategies, we noticed that; Strategy 1 (practising physical or social distancing protocols) is the most cost-saving and most effective control intervention in Saudi Arabia in the absence of vaccination. But, in terms of the infection averted, we saw that strategy 6, strategy 11, strategy 12, and strategy 14 are just as good in controlling COVID-19.Entities:
Keywords: Control strategies; Cost minimizing analysis; Economic health outcomes; Existence of optimal control
Year: 2022 PMID: 35070649 PMCID: PMC8760146 DOI: 10.1016/j.rinp.2022.105177
Source DB: PubMed Journal: Results Phys ISSN: 2211-3797 Impact factor: 4.476
Model’s parameter descriptions and values.
| Parameter | Definition | Value | Source |
|---|---|---|---|
| Recruitment rate | |||
| Natural mortality rate | |||
| Contact rate among exposed and susceptible | 0.1233 | ||
| Contact rate among infected (symptomatic) and susceptible | 0.0542 | ||
| Contact rate among infected (asymptomatic) and susceptible | 0.0020 | ||
| Contact rate among environment and susceptible | 0.1101 | ||
| Incubation period | 0.1980 | ||
| fraction that transient to | 0.3085 | ||
| Natural death rate due to Infection at I | 0.0104 | ||
| Recovery from I | 0.3680 | ||
| Recovery from A | 0.2945 | ||
| Virus contribution due to E to B | 0.2574 | ||
| Virus contribution due to I to B | 0.2798 | ||
| Virus contribution due to A to B | 0.1584 | ||
| Virus removal from environment | 0.3820 |
Fig. 1Single control strategy.
Fig. 2Double control strategies.
Fig. 3Implementation of quadruplet controls.
Fig. 4With and without control strategies.
Fig. 5With and without control strategies.
Incremental cost-effectiveness ratio for scenario A.
| Strategy | Infection averted | Cost | IAR | ACER | ICER |
|---|---|---|---|---|---|
| Strategy 3: | 1.2325 | ||||
| Strategy 2: | 1.5835 | ||||
| Strategy 4: | 1.2914 | 0.0016 | 0.0100 | ||
| Strategy 1: | 281.1135 | 1.5793 | −0.0004 |
Incremental cost-effectiveness ratio for scenario A.
| Strategy | Infection averted | Cost | IAR | ACER | ICER |
|---|---|---|---|---|---|
| Strategy 3: | 1.2325 | ||||
| Strategy 2: | 1.5835 | ||||
| Strategy 1: | 281.1135 | 1.5793 | −0.0028 |
Incremental cost-effectiveness ratio for scenario A.
| Strategy | Infection averted | Cost | IAR | ACER | ICER |
|---|---|---|---|---|---|
| Strategy 2: | 1.5835 | ||||
| Strategy 1: | 281.1135 | 1.5793 | −0.0028 |
Incremental cost-effectiveness ratio for scenario B.
| Strategy | Infection averted | Cost | IAR | ACER | ICER |
|---|---|---|---|---|---|
| Strategy 8: | 1.4524 | 0.0015 | 0.0015 | ||
| Strategy 10: | 1.3350 | 0.0021 | 0.0232 | ||
| Strategy 9: | 1.4077 | 0.0020 | |||
| Strategy 6: | 1.5239 | −0.0631 | |||
| Strategy 7: | 1.4506 | 0.0068 | |||
| Strategy 5: | 1.5759 | −0.0016 |
Incremental cost-effectiveness ratio for scenario B.
| Strategy | Infection averted | Cost | IAR | ACER | ICER |
|---|---|---|---|---|---|
| Strategy 8: | 1.4524 | 0.0015 | 0.0015 | ||
| Strategy 9: | 1.4077 | 0.0020 | 0.0094 | ||
| Strategy 6: | 1.5239 | −0.0631 | |||
| Strategy 7: | 1.4506 | 0.0068 | |||
| Strategy 5: | 1.5759 | −0.0016 |
Incremental cost-effectiveness ratio for scenario B.
| Strategy | Infection averted | Cost | IAR | ACER | ICER |
|---|---|---|---|---|---|
| Strategy 8: | 1.4524 | 0.0015 | 0.0015 | ||
| Strategy 6: | 1.5239 | −0.0078 | |||
| Strategy 7: | 1.4506 | 0.0068 | |||
| Strategy 5: | 1.5759 | −0.0016 |
Incremental cost-effectiveness ratio for scenario B.
| Strategy | Infection averted | Cost | IAR | ACER | ICER |
|---|---|---|---|---|---|
| Strategy 8: | 1.4524 | 0.0015 | 0.0015 | ||
| Strategy 6: | 1.5239 | −0.0078 | |||
| Strategy 5: | 1.5759 | 0.0030 |
Incremental cost-effectiveness ratio for scenario B.
| Strategy | Infection averted | Cost | IAR | ACER | ICER |
|---|---|---|---|---|---|
| Strategy 8: | 1.4524 | 0.0015 | 0.0015 | ||
| Strategy 6: | 1.5239 | −0.0078 |
Incremental cost-effectiveness ratio for scenario C.
| Strategy | Infection averted | Cost | IAR | ACER | ICER |
|---|---|---|---|---|---|
| Strategy 13: | 1.4022 | 0.0024 | 0.0024 | ||
| Strategy 11: | 1.5641 | 0.0010 | −0.0229 | ||
| Strategy 12: | 1.4706 | – |
Application of optimal controls: scenario D.
| Strategy | Infection averted | Cost | IAR | ACER |
|---|---|---|---|---|
| Strategy 14: | 1.4662 |
Fig. 6IAR and ACER for the most-effective strategies in Scenarios A–D.
Incremental cost-effectiveness ratio for the most-effective strategies.
| Strategy | IA | Cost | IAR | ACER | ICER |
|---|---|---|---|---|---|
| Strategy 1: | 2.0679 | 281.1135 | 1.5793 | ||
| Strategy 6: | 2.1128 | 1.5239 | 0.0238 | ||
| Strategy 14: | 2.2265 | 1.4662 | 0.0061 | ||
| Strategy 12: | 2.2265 | 1.4706 | – |
Incremental cost-effectiveness ratio for the most-effective strategies.
| Strategy | IA | Cost | IAR | ACER | ICER |
|---|---|---|---|---|---|
| Strategy 1: | 2.0679 | 281.1135 | 1.5793 | ||
| Strategy 14: | 2.2265 | 1.4662 | 0.0111 | ||
| Strategy 12: | 2.2265 | 1.4706 | – |
Incremental cost-effectiveness ratio for the most-effective strategies.
| Strategy | IA | Cost | IAR | ACER | ICER |
|---|---|---|---|---|---|
| Strategy 1: | 2.0679 | 281.1135 | 1.5793 | ||
| Strategy 12: | 2.2265 | 1.4706 | 0.0100 |